0001209191-23-056355.txt : 20231121
0001209191-23-056355.hdr.sgml : 20231121
20231121180022
ACCESSION NUMBER: 0001209191-23-056355
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231117
FILED AS OF DATE: 20231121
DATE AS OF CHANGE: 20231121
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Teehan Brendan
CENTRAL INDEX KEY: 0001891900
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50768
FILM NUMBER: 231429411
MAIL ADDRESS:
STREET 1: C/O ACADIA PHARMACEUTICALS INC.
STREET 2: 12830 EL CAMINO REAL, SUITE 400
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001070494
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 061376651
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12830 EL CAMINO REAL
STREET 2: SUITE 400
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 858-558-2871
MAIL ADDRESS:
STREET 1: 12830 EL CAMINO REAL
STREET 2: SUITE 400
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-11-17
0
0001070494
ACADIA PHARMACEUTICALS INC
ACAD
0001891900
Teehan Brendan
C/O ACADIA PHARMACEUTICALS INC.
12830 EL CAMINO REAL, SUITE 400
SAN DIEGO
CA
92130
0
1
0
0
EVP, COO, Head of Commercial
0
Common Stock
2023-11-17
4
M
0
4956
A
30397
D
Common Stock
2023-11-17
4
M
0
4956
A
35353
D
Common Stock
2023-11-20
4
S
0
4960
22.64
D
30393
D
Restricted Stock Units
2023-11-17
4
M
0
4956
0.00
D
Common Stock
4956
19826
D
Restricted Stock Units
2023-11-17
4
M
0
4956
0.00
D
Common Stock
4956
19826
D
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Includes 707 and 378 shares of the Issuer's common stock acquired by the reporting person on May 15, 2023 and November 15, 2023, respectively, pursuant to an employee stock purchase program.
The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.64 to $22.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.
The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.
/s/ Austin D. Kim, Attorney-in-Fact
2023-11-21